Transarterial Ethanol Ablation(TEA) for Unresectable Hepatocellular Carcinoma(HCC)

NACompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

July 31, 2017

Study Completion Date

July 31, 2017

Conditions
Hepatocellular Carcinoma
Interventions
PROCEDURE

TEA

Arterial feeders to tumors were identified and catheterized with a microcatheter to a branch supplying a Couinaud segment or subsegmental level for delivery of the therapeutic agent, which was Lipiodol-ethanol mixture at 2:1 ratio by volume for TEA (Lipiodol Ultrafluide, Guerbet, France; Dehydrated alcohol \[absolute alcohol\], Martindale Pharmaceuticals, United Kingdom). The agents were delivered under fluoroscopic control to completely fill up the vasculature of all tumors. The maximum total volume of Lipiodol-ethanol mixture or cisplatin emulsion to be delivered in one treatment session was 60 mL.

Trial Locations (3)

Unknown

Department of Clinicl Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong

Department of Imaging and Interventional Radiology, Prince of Wales Hospital, The Chinsese University of Hong Kong, Hong Kong

Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong

All Listed Sponsors
collaborator

Prince of Wales Hospital, Shatin, Hong Kong

OTHER

lead

Chinese University of Hong Kong

OTHER

NCT01837381 - Transarterial Ethanol Ablation(TEA) for Unresectable Hepatocellular Carcinoma(HCC) | Biotech Hunter | Biotech Hunter